TNYA Key Statistics, Chart & Performance
The current stock price of TNYA is 1.36 USD. In the past month the price decreased by -11.69%. In the past year, price decreased by -50.55%.
TNYA Latest News, Press Relases and Analysis
TNYA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.7 | 395.86B | ||
| AMGN | AMGEN INC | 14.51 | 170.90B | ||
| GILD | GILEAD SCIENCES INC | 15.04 | 152.86B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.69 | 113.14B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.59 | 78.49B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 809.08 | 54.51B | ||
| INSM | INSMED INC | N/A | 41.64B | ||
| NTRA | NATERA INC | N/A | 31.89B | ||
| BIIB | BIOGEN INC | 10.3 | 25.31B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.51 | 21.04B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.24B | ||
| INCY | INCYTE CORP | 14.97 | 18.87B |
Related stock screener links
About TNYA
Company Profile
Tenaya Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for cardiovascular diseases. The company is headquartered in South San Francisco, California and currently employs 97 full-time employees. The company went IPO on 2021-07-30. Its pipeline includes TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to deliver a working MYBPC3 gene to heart muscle cells via a single intravenous infusion, increasing MyBP-C protein levels to address the underlying cause of MYBPC3-associated HCM with the aim of halting or even reversing disease after a single dose. Its MyPEAK-1 Phase I b/2 clinical trial is an ongoing, multi-center, open-label, dose-escalating study designed to assess the safety, tolerability and clinical efficacy of a one-time intravenous infusion of TN-201 gene replacement therapy. TN-401 is its AAV9-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene.
Company Info
TENAYA THERAPEUTICS INC
171 Oyster Point Blvd., Suite 500
South San Francisco CALIFORNIA US
CEO: Faraz Ali
Employees: 97
Phone: 14158652066
TENAYA THERAPEUTICS INC / TNYA FAQ
Can you describe the business of TENAYA THERAPEUTICS INC?
Tenaya Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for cardiovascular diseases. The company is headquartered in South San Francisco, California and currently employs 97 full-time employees. The company went IPO on 2021-07-30. Its pipeline includes TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to deliver a working MYBPC3 gene to heart muscle cells via a single intravenous infusion, increasing MyBP-C protein levels to address the underlying cause of MYBPC3-associated HCM with the aim of halting or even reversing disease after a single dose. Its MyPEAK-1 Phase I b/2 clinical trial is an ongoing, multi-center, open-label, dose-escalating study designed to assess the safety, tolerability and clinical efficacy of a one-time intravenous infusion of TN-201 gene replacement therapy. TN-401 is its AAV9-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene.
What is the current price of TNYA stock?
The current stock price of TNYA is 1.36 USD. The price decreased by -2.86% in the last trading session.
Does TENAYA THERAPEUTICS INC pay dividends?
TNYA does not pay a dividend.
How is the ChartMill rating for TENAYA THERAPEUTICS INC?
TNYA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for TNYA stock?
15 analysts have analysed TNYA and the average price target is 10.35 USD. This implies a price increase of 660.72% is expected in the next year compared to the current price of 1.36.
What is the GICS sector and industry of TNYA stock?
TENAYA THERAPEUTICS INC (TNYA) operates in the Health Care sector and the Biotechnology industry.
What is TENAYA THERAPEUTICS INC worth?
TENAYA THERAPEUTICS INC (TNYA) has a market capitalization of 226.45M USD. This makes TNYA a Micro Cap stock.
TNYA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to TNYA. When comparing the yearly performance of all stocks, TNYA is a bad performer in the overall market: 84.7% of all stocks are doing better.
TNYA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TNYA. TNYA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
TNYA Financial Highlights
Over the last trailing twelve months TNYA reported a non-GAAP Earnings per Share(EPS) of -0.78. The EPS increased by 45.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -89.94% | ||
| ROE | -113.94% | ||
| Debt/Equity | 0 |
TNYA Forecast & Estimates
15 analysts have analysed TNYA and the average price target is 10.35 USD. This implies a price increase of 660.72% is expected in the next year compared to the current price of 1.36.